HUMULIN 70/30
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Apr 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
HUMULIN 70/30 by Eli Lilly and Company is 70/30 lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Approved for glycemic control in adults with diabetes mellitus. First approved in 1989.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMULIN 70/30 is a fixed-combination human insulin injection containing 70% NPH (intermediate-acting) and 30% regular (rapid-acting) insulin for subcutaneous administration. It is indicated for the treatment of diabetes mellitus in patients requiring insulin therapy. This combination formulation provides both basal and mealtime insulin coverage in a single injection.
LOE Approaching
As a decades-old product approaching loss of exclusivity with moderate competitive pressure (30/100), this brand faces declining revenue and team consolidation risk.
Mechanism of Action
70/30 lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
Indications (1)
Career Relevance
Working on HUMULIN 70/30 offers limited career acceleration due to the product's mature lifecycle and approaching loss of exclusivity. Roles available are primarily defensive (account management, pricing strategy, formulary protection) rather than growth-oriented, making this assignment suitable for experienced professionals managing decline rather than launching growth initiatives.
Worked on HUMULIN 70/30 at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.